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Background: This study compares two latest-generation self-expanding transcatheter heart valves (THV), 
the supra-annular ACURATE neo (Boston Scientific) and the intra-annular Centera THV (Edwards 
Lifesciences).
Methods: In this single center observational cohort trial 317 patients treated with the ACURATE neo and 
78 patients treated with the Centera TVH were included. The main endpoints were device success and the 
early safety endpoint at 30 days. 
Results: Besides higher incidence of diabetes mellitus and higher body mass index in patients treated 
with the ACURATE neo THV, there were no baseline differences between the groups. Device success was 
similar in both groups (neo: 91.8% vs. Centera: 93.6%; P=0.598), with numerically higher rates of moderate 
to severe paravalvular leakage in the ACURATE neo group (4.7% vs. 1.3%; P=0.214). At 30 days all-cause 
mortality rates were low in both groups (0.3% vs. 0%; P=0.620) and no difference occurred in the early safety 
at 30 days (19.3% vs. 16.7%; P=0.599). However, all-cause stroke rates were significantly higher in patients 
treated with the Centera THV (6.4 vs. 1.6%; P=0.015).
Conclusions: The ACURATE neo and the Centera THV show low mortality rates as well as comparable, 
favorable hemodynamics. The finding of higher stroke rates at 30 days with the repositionable Centera SE-
THV needs further assessment.
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Introduction
Over the last decades transcatheter aortic valve implantation 
(TAVI) evolved from a therapeutic technique reserved 
for otherwise inoperable patients to the standard of care 
for high- and intermediate-risk patients suffering from 
severe aortic valve stenosis. Only recently, evidence 
from prospective randomized clinical trials extended this 
indication to low-risk (1,2).
With technological advances of transcatheter heart 
valves (THV), increasing operator experience and use of 
low-profile delivery systems, procedural outcomes have 
improved considerably, reducing one-year mortality from 
24% (3) in high-risk patients to 12% in intermediate risk-
patients (4).
While first generation self-expanding (SE) THV have 
been associated with higher rates of paravalvular leakage 
(PVL), increased permanent pacemaker implantation (PPI) 
and more need for multiple valves (5), next generation SE-
THV substantially mitigated these hazards. For instance, 
low PPI rates ranging from 2.3% to 9.9% have been 
described with the ACURATE neo SE-THV (Boston 
Scientific, Marlborough, Massachusetts, USA) (6,7), 
however at the cost of more than mild PVL rates of 5% (8,9). 
Recently, the Centera SE-THV (Edwards Lifesciences, 
Irvine, California, USA) showed promising initial results 
with low PPI rates of 4.9% and very low incidence of more 
than mild PVL <1% (10). 
Among a number of important valve components, leaflet 
mounting within the stented frame relative to the native 
aortic annulus, i.e., supra-annular or intra-annular design 
is of extraordinary relevance owing to expected differences 
in valve hemodynamics and procedural specifications. A 
supra-annular THV is designed to avoid interference with 
the native annulus preventing blood flow obstruction, 
thus leading to lower transvalvular gradients and higher 
effective orifice areas (EOAs) (11). On the other hand, an 
intra-annular THV mimics aortic anatomy and bears the 
potential advantage of less interaction with the coronary 
arteries, possibly preventing obstruction.
Despite the recent market withdrawal of the Centera 
SE-THV, we aimed to investigate whether its intra-
annular design may result in improved outcome with 
regards to established updated Vascular Academic Research 
Consortium (VARC-2) endpoints compared with the supra-
annular design of the ACURATE Neo SE-THV.
We present the following article in accordance with the 
“Strengthening the Reporting of Observational Studies in 




Between January 2014 and July 2019, 1,561 patients 
underwent transfemoral TAVI for severe native aortic valve 
stenosis at the Klinik für Herz-und Kreislauferkrankungen, 
Deutsches Herzzentrum München, Munich, Germany. Of 
these, only patients treated with the Centera (n=78) or the 
ACURATE neo SE-THV (n=317) were considered for 
the current analysis, resulting in a final study population 
of 395 patients. Indication for TAVI was discussed 
by a multidisciplinary heart team and consensus was 
achieved regarding the minimal-invasive TAVI approach 
in all cases. The final decision on prosthesis type and 
size was left to the discretion of the treating physician 
considering anatomical features, calcification and the 
manufacturer’s recommendations. All patients provided 
written informed consent prior to the procedure. Clinical 
data was collected by hospital chart reviews at the time 
of TAVI and entered in a dedicated database. Multi-Slice 
Computed Tomography (MS-CT) was available in 392/395 
patients and measurements were performed as previously 
described (12) using 3MensioTM (Pie Medical, The 
Netherlands). Severity of calcification of the aortic valve 
was visually assessed and dichotomized in mild-moderate 
vs. severe. The study was conducted in accordance with the 
Declaration of Helsinki (as revised in 2013) and approved 
by the institutional board (5009/11).
Device description
The Centera SE-THV is a contour shaped, SE nitinol 
valve with intra-annular design and bovine pericardial 
leaflets, which gained CE mark in February 2018. In August 
2019 Edwards Lifesciences decided to discontinue its 
production. Technical features have been described in detail 
elsewhere (10). In short, it is transfemorally delivered 
through an expandable 14 French E-sheath (Edwards 
Lifesciences, Irvine, CA, USA) with a steerable delivery 
catheter for precise positioning. The THV is pre-mounted 
on the delivery system and is released through a motorized 
handle, allowing recapturing and repositioning. Three 
different valve diameters (23, 26 and 29 mm) cover an 
annulus range from 18 to 26 mm. Twenty-seven patients 
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of this analysis were treated with the first iteration of the 
Centera SE-THV, which had a longer stiff end compared 
with the current THV.
The ACURATE neo SE-THV gained CE mark in 2014 
and its technical features have been described elsewhere (9). 
Shortly, it features a supra-annular design with porcine 
pericardial leaflets mounted on a nitinol frame with 
pericardial sealing-skirt. The sizes “Small”, “Medium” and 
“Large” cover an annulus range from 21 to 27 mm. It is 
transfemorally delivered through an 18 to 20 French sheath. 
More recently a new expandable sheath, the iSLEEVE 
sheath (Boston Scientific, Marlborough, Massachusetts, 
USA) with a 14-French diameter became available.
Definition of endpoints and follow-up
All data and clinical endpoints of this analysis were 
prospectively collected and classified according to the 
VARC-2 definitions (13). The primary endpoint was the 
combined endpoint “Device success”, including absence of 
procedural mortality, correct positioning of a single THV 
into the proper anatomic location, and intended performance 
of the THV (no prosthesis-patient mismatch, mean 
aortic valve gradient <20 mmHg or peak velocity <3 m/s, 
with no moderate or severe valve regurgitation) and no need 
of conversion to sternotomy. Furthermore, the endpoint 
“procedural success”, a composite of successful vascular 
access, delivery and deployment of the device and successful 
retrieval of the delivery system, was assessed. 
During follow-up the combined endpoint “early safety 
at 30 days”, which is a composite of all-cause mortality, all 
stroke, life-threatening bleeding and acute kidney injury 
(stage 2 or 3 or renal replacement therapy), coronary 
artery obstruction requiring intervention, major vascular 
complication and valve-related dysfunction requiring a 
repeated procedure was computed. For this endpoint, a 
time to first event analysis was performed and patients were 
censored after the first event. In order to establish clinical 
benefit from the procedure, New York Heart Association 
(NYHA) functional class was recorded prior to TAVI and at 
30 days. Valve dysfunction was assessed by echocardiography 
at 30 days and included mean transvalvular transaortic 
gradient ≥20 mmHg, PVL II+ or effective orifice area 
(EOA) ≤0.9 cm2. Neurological assessment was performed 
by an independent neurologist and was based on clinical 
manifestations and neuroimaging and was adjudicated 
according to VARC-2 recommendations. Follow-up data 
were prospectively collected during routine ambulatory 
visits at the outpatients’ clinic, by referring to the treating 
physician, hospital documentation or through telephone 
interview.
Statistical analysis
Continuous variables are expressed as mean with standard 
deviation or median with interquartile range. Event 
rates during follow-up were calculated as Kaplan-Meier 
estimates, P values for group comparison were generated 
using the log rank test. To investigate factors associated with 
the primary endpoint, a multivariable logistic regression 
model was computed adjusting for imbalances in baseline 
characteristics derived from univariate analysis. Factors 
were entered in the multivariable logistic regression model 
if they achieved significant P value <0.05 by univariate 
analysis (Online Resource Table S1). Choice of THV model 
was included independently of its P value in univariate 
analyses in order to assess its impact on the primary 
endpoint. To account for differences for the secondary 
endpoint, a Cox proportional hazards regression model was 
computed, adjusting for variables yielding a P value <0.05 in 
the univariate analysis (Online Resource Table S2).
A 2-sided P value of <0.05 was considered statistically 
significant for all analyses. IBM SPSS Statistics (Version 
25, SPSS Inc., Chicago, Illinois, USA) and R (Version 




The mean age of the study population was 81.0±6.0 years, 
53.4% were female and the median EuroScore I was 13.5% 
[8.0–21.0]. Baseline characteristics according to THV are 
displayed in Table 1. Despite a higher body mass index and 
a higher rate of diabetes mellitus in the ACURATE neo 
group, demographics, preoperative risk stratification and 
symptom severity were equally distributed. Furthermore, 
there were no differences in baseline echocardiography, 
ECG or anatomic features measured by MS-CT (Table 1).
Procedural outcome and device success
The small, medium and large ACURATE neo SE-THV 
were implanted in 30.9%, 38.2% and 30.9%, respectively, 
whereas the Centera SE-THV 23, 26 and 29 mm were 
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deployed in 14.1%, 53.8% and 32.1%, respectively. 
Procedural characteristics and outcome according to 
implanted THV are displayed in Table 2. Patients in both 
groups were predilated in >98% of cases, while patients 
treated with the ACURATE neo SE-THV more often 
required post-dilatation (60.6% vs. 48.7%; P=0.057), 
resulting in longer procedural time (57.5±22.1 vs. 
48.1±17.4 min; P<0.001) and fluoroscopy time [12.8 
(10.4–16.3) vs. 10.9 (9.0–13.5) min; P<0.001]. Procedural 
success was similar between the two groups (98.4% vs. 
96.2%; P=0.196): for the ACURATE neo SE-THV, 
procedural failure was caused by annulus rupture in two 
cases and valve embolization in three cases. In two patients 
treated with the Centera SE-THV, the valve could not be 
deployed and had to be retrieved due to missing annulus 
alignment, while one case showed severe valve recoil even 
after post-dilatation, requiring deployment of a second 
THV.
There was no difference in the primary endpoint device 
success between the groups (91.8% vs. 93.6%; P=0.598). 
Failure to achieve the endpoint was driven by residual 
PVL II+ in most cases, which was numerically higher 
Table 1 Baseline characteristics
Characteristics Centera (n=78) ACURATE neo (n=317) P value
Clinical characteristics
Age (years) 81.2±5.9 80.9±6.1 0.648
Female gender 43 (55.1) 168 (53.0) 0.735
Body mass index (kg/m
2
) 25.5±5.2 26.6±4.5 0.047
EuroScore I 13.5 [9.0–20.2] 13.3 [8.0–21.1] 0.963
NYHA III/IV 46 (59.0) 193 (60.9) 0.757
Chronic obstructive pulmonary disease 12 (15.4) 39 (12.3) 0.467
Diabetes mellitus 11 (14.1) 83 (26.2) 0.025
Glomerular filtration rate (mL/min) 55.1±19.4 52.8±19.2 0.332
Peripheral vascular disease 10 (12.8) 39 (12.3) 0.901
Previous stroke major/minor 12 (15.4) 44 (13.9) 0.733
Coronary artery disease 67 (85.9) 271 (85.5) 0.927
Previous coronary artery bypass grafting 9 (11.5) 37 (11.7) 0.974
Echocardiography
Left ventricular ejection fraction <35% 4 (5.1) 20 (6.3) 0.696
Pulmonary hypertension
a
9 (11.5) 27 (8.5) 0.406
ECG
Atrial fibrillation 24 (30.8) 127 (40.1) 0.130
Right bundle branch block 7 (9.0) 21 (6.6) 0.469
Left bundle branch block 6 (7.7) 29 (9.1) 0.685
Previous pacemaker 8 (10.3) 32 (10.1) 0.966
Multislice-computer tomography data
b
Aortic annular area (cm
2
) 4.2±0.6 4.2±0.7 0.783
Severely calcified 14 (18.2) 56 (17.8) 0.934
Data are mean ± standard deviation, median [interquartile range] or n (%). 
a
, pulmonary arterial pressure on echocardiography ≥60 mmHg; 
b
, 
available for 392/395 patients; NYHA, New York Heart Association functional class. 
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Table 2 Procedural characteristics and in-hospital complications
Characteristics Centera (n=78) ACURATE neo (n=317) P value
Procedural data
Conscious sedation 73 (93.6) 123 (38.8) <0.001
Pre-dilatation 77 (98.7) 317 (100.0) 0.197
Post-dilatation 38 (48.7) 192 (60.6) 0.057
Procedural time (min) 48.1±17.4 57.5±22.1 <0.001
Contrast (mL) 140.6±39.7 141.5±47.3 0.886
Fluoroscopy time (min) 10.9 [9.0–13.5] 12.8 [10.4–16.3] <0.001
Oversizing by area (%) 32.7±8.5 48.6±14.3 <0.001
Procedural success
a
75 (96.2) 312 (98.4) 0.196
Coronary impairment 0 (0) 1 (0.3) 0.999
Procedural death 0 (0) 1 (0.3) 0.999
In-hospital complications
All-stroke 4 (5.1) 4 (1.3) 0.052
Disabling stroke 2 (2.6) 2 (0.6) 0.176
Non-disabling stroke 2 (2.6) 2 (0.6) 0.176
Major vascular complication 8 (10.3) 54 (17.0) 0.140
Life-threatening bleeding 3 (3.8) 14 (4.4) 0.999
Renal failure (AKIN 2/3, including dialysis) 0 (0) 4 (1.3) 0.999
New permanent pacemaker implantation
b
5 (7.1) 24 (8.4) 0.726
In-hospital mortality 0 (0) 1 (0.3) 0.999
Data are mean ± standard deviation, median [interquartile range] or n (%). 
a
, composite of successful vascular access, delivery and deployment 
of the device, successful retrieval of the delivery system; 
b
, for patients without previous pacemaker. AKIN, acute kidney injury network. 
Table 3 Device success and individual components
Characteristics Centera (n=78) ACURATE neo (n=317) P value
Device success
a
73 (93.6) 291 (91.8) 0.598
Intended performance
b
75 (96.2) 296 (93.4) 0.439
Paravalvular leakage ≥ II° 1 (1.3) 15 (4.7) 0.214
Elevated gradients ≥20 mmHg 0 (0) 6 (1.9) 0.603
Correct position 76 (97.4) 316 (99.7) 0.101
Conversion to sternotomy 1 (1.3) 2 (0.6) 0.484
Multiple valves 3 (3.8) 6 (1.9) 0.389
Procedural death 0 (0) 1 (0.3) 0.999
a
, multiple events possible; 
b
, no prosthesis mismatch, mean aortic valve gradient <20 mmHg, or peak velocity <3 m/s, without moderate 
or severe prosthetic valve aortic regurgitation of the first implanted prosthesis.
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in the ACURATE neo group (4.7% vs. 1.3%; P=0.214). 
Table 3 shows the individual components of this VARC-2 
endpoint. By multivariate regression analysis, there was 
no association between valve type and device success [odds 
ratio, 1.410; 95% confidence interval (CI): 0.518–3.840; 
P=0.502]. Online Resource Figure S1 shows that there is no 
significant learning curve through tertiles of consecutively 
treated patients for both THVs.
In-hospital outcome
In-hospital complications were similar among the two 
groups, however there was a non-significant trend towards 
higher stroke rates in patients treated with the Centera 
SE-THV (5.1% vs. 1.3%; P=0.052). Patients treated with 
the ACURATE neo SE-THV had numerically higher 
rates of major vascular complications (17.0% vs. 10.3%; 
P=0.140). However, when considering patients treated with 
ACURATE neo SE-THV with use of a 14-French sheath 
rather than larger sheaths there was a reduction from 17.6% 
to 15.3% of vascular complications.
30-day result and early safety composite endpoint
Clinical follow-up was complete for all patients (n=395). 
From discharge to 30 days no patient died, resulting in 
an all-cause mortality at 30 days of 0.2% (1/365). Figure 1 
shows no significant difference in the composite early safety 
endpoint at 30 days between the two groups (ACURATE 
neo: 19.3% vs. Centera THV: 16.7%; P=0.599). Event rates 
at 30 days according to implanted THV are depicted in 
Table 4. In a Cox proportional hazards regression model, 
female gender, left and right bundle branch block were 
independent predictors of the early safety endpoint at 
30 days, while the deployed THV showed no significant 
association (Online Resource Table S3). Online Resource 
Figure S2 shows that there was no significant learning curve 
through tertiles of consecutively treated patients for both 
THVs.
Except for stroke rates, which were significantly lower in 
the ACURATE neo compared to the Centera group (1.6% 
vs. 6.4%; P=0.015), there were no differences between the 
THVs.
Figure 2 pictures the distribution across NYHA classes 
prior to procedure and at 30 days after TAVI according to 
THV: for both valves >92% of patients were in NYHA class 
I or II at 30 days (92.3% vs. 94.7%; P=0.463).
At 30 days, echocardiographic evaluation was available 
for 92.7% of patients treated with the ACURATE neo and 
for 94.9% of patients treated with the Centera SE-THV. 
Mean transvalvular gradient after procedure was low for 
both valves showing no significant difference and remained 
stable at 30 days (Figure 3).
Discussion
The present study compared the procedural and 30 days 
outcome of two contemporary SE-THVs. The main 
findings can be summarized as follows: firstly, both THV 
showed excellent procedural outcome with comparable rates 
of device success; the ACURATE neo SE-THV showed a 
non-significant trend of higher rates of residual PVL II+. 
Secondly, symptomatic benefit was high with these devices, 
with comparable rates of the early safety endpoint at 30 days. 
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Figure 2 NYHA Functional class at baseline and at 30 days after procedure according to the implanted THV. THV, transcatheter heart valves. 
Table 4 Outcome at 30 days with Kaplan-Meier estimates
Outcome Centera (n=78) ACURATE neo (n=317) P value
Early safety composite endpoint at 30 days
a
13 (16.7) 61 (19.3) 0.599
All-cause mortality 30 days 0 (0) 1 (0.3) 0.620
All stroke (disabling, non-disabling) 5 (6.4) 5 (1.6) 0.015
Coronary artery obstruction requiring intervention 0 (0) 1 (0.3) 0.620
Major vascular complication 8 (10.7) 54 (17.1) 0.169
Life-threatening bleeding 4 (5.1) 14 (4.4) 0.797
Acute kidney injury (AKIN 2/3, including renal replacement) 0 (0) 4 (1.3) 0.319
Valve-related dysfunction requiring repeat procedure 0 (0) 0 (0) –
New permanent pacemaker implantation
b
5 (7.1) 29 (10.2) 0.438
a
, multiple events possible; counting only first event; 
b
, for patients without previous pacemaker. AKIN, acute kidney injury network; BAV, 
balloon aortic valvuloplasty; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
Noteworthy, the Centera SE-THV was associated with 
significantly higher stroke rates at 30 days.
Procedural outcome and device success
The composite endpoint device success was proposed by 
VARC to ensure a measurement of short-term procedural 
outcome and THV function. For the ACURATE neo 
SE-THV reported rates of device success range from 
89–98% (8,9,14), while for the Centera SE-THV data is 
limited to the Centera EU study, which reported device 
success in 96% with a residual PVL II+ rate of 0.6% (10). 
Consistent with other reports (8,9,14), we found a non-
significant trend of higher residual PVLII+ rates of 
4.7% in the ACURATE neo compared to 1.3% with the 
Centera SE-THV. This finding may be explained by the 
relatively lower radial force of the ACURATE neo SE-
THV, and the novel contoured shape of the Centera SE-
THV resulting in improved sealing of the aortic annulus. 
The low PVLII+ rates found with the Centera SE-THV 
compares favorably to other contemporary SE-THV such 
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USA), where PVLII+ rates between 0–5.7% were reported 
(14,15), and the Portico THV (Abbott, Abbott Park, 
Illinois, USA) with PVLII+ rates between 2.6–8.2% 
(16,17). Considering the adverse impact of residual PVL 
on outcome, further improvement should be paramount to 
reduce this hurdle with the ACURATE neo SE-THV. In 
fact, a new iteration of this THV, the ACURATE neo 2.0, 
featuring an additional sealing skirt is currently in CE mark 
studies. The possibility of recapturing and repositioning 
may have also contributed to mitigate the PVL rates with 
the Centera SE-THV, especially in a subset of patients 
with severely calcified aortic annuli. However, results with 
the repositionable Evolut Pro show PVL rates comparable 
with non-repositionable THVs. Thus, possible advantages 
of repositioning to achieve lower PVL rates should be 
weighed against potential downsides through manipulation 
in calcified anatomies, such as longer procedural times and 
increased risk of stroke.
Besides PVL, hemodynamic performance of THV is 
important and increased transvalvular gradients bear a 
potentially detrimental impact on long-term durability. 
Despite its intra-annular design, the Centera THVs 
showed low, single digit transvalvular gradients at discharge 
and at 30 days, comparable to the ACURATE neo and 
similar to those described with other latest generation SE 
THVs (18,19). A possible explanation of the favorable 
hemodynamic performance of the Centera valve may be 
related to its geometric design, which mimics the natural 
aortic root anatomy providing adaptive sealing of the 
natural annulus, with reduced tissue interference resulting 
in physiological flow and low transvalvular gradients.
Early safety at 30 days
The early safety endpoint at 30 days summarizes important 
measures of complications and mortality and was proposed 
for the assessment of short-term patient safety after TAVI. In 
the present analysis we found comparable cumulative rates 
for both analyzed THVs, namely 19.3% for the ACURATE 
neo and 16.7% for the Centera THV. Similar rates ranging 
from 8.6% to 17.9% (8,9,14,20) can be found for the 
ACURATE neo SE-THV as well as for other contemporary 
SE platforms, between 11–15% for the Evolut PRO (14,15), 
14–22% for the Portico platform (18,21). Whereas, this 
endpoint has not yet been reported for the Centera SE-THV. 
All-cause mortality was very low in the entire population and 
while there was no difference in most clinical endpoints at 30 
days, two findings are worthy of discussion.
Firstly, patients treated with the Centera SE-THV 
showed significantly higher stroke rates at 30 days compared 
to patients treated with the ACURATE neo SE-THV. 
Recently, an analysis including more than 100,000 TAVI 
patients over 5-year reported a stroke rate of 2.3% at 30 days 
and interestingly, there was no difference over the inclusion 
period despite the evolution of THV technology (22). 
The ACURATE neo compares favorably to these data 
with reports of all stroke of 2% (8,14,23). Comparably 
stroke rates of 1.7–2.8% were found with the Evolut PRO 
(14,15,24) and rates ranging from 1.6% to 3% for the 
Portico THV (18,25). Importantly, the stroke rates of the 
current analysis have to be interpreted with caution: the 
sample size of the current analysis is limited resulting in 
relative inflation of rare complications such as stroke and 
others. In the current analysis no cerebral protection devices 
Figure 3 Mean transvalvular gradients according to THV before TAVI, at discharge and at 30 days. THV, transcatheter heart valves; TAVI, 
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were used, which might have mitigated cerebral embolic risk. 
A possible explanation for the higher stroke rate in Centera 
SE-THV may be an increased interaction of the steerable 
distal part of the Centera delivery catheter in the aortic 
arch and ascending aorta, as well as increased manipulation 
of the aortic valve apparatus during recapturing and 
repositioning. Importantly, there was no difference in stroke 
rates between the first iteration of the Centera SE-THV and 
the second (data not shown). Since additional studies with 
increased sample size are unlikely to be performed with the 
Centera SE-THV, the findings of the current study may be 
considered hypothesis-generating for future SE valve design, 
especially for valves of intra-annular design.
Vascular complications were numerically higher in 
patients treated with the ACURATE neo SE-THV, which 
may be explained by the relatively larger sheath size 
(18–20 French) used when the ACURATE neo SE-THV 
was introduced into market. With introduction of lower 
profile sheaths, this specific complication is likely to 
decrease. Indeed, Kim et al. showed a significant reduction 
of vascular complication when using only the expandable 
mesh component of the transGlide introducer system with 
an inner diameter to 13 French compared to larger sheath 
sizes (26).
Limitations
To our knowledge this is the first analysis comparing the 
ACURATE neo SE-THV and Centera SE-THV. Albeit 
including a 395 patients strong, real-world population 
treated at a high-volume center and presenting complete 
data, including 30 days follow-up, this analysis carries some 
limitations: first of-all, this is an observational study with 
self-adjudication of events, lacking a central core-laboratory. 
Further, despite a homogenous patient population presenting 
few baseline differences, which were accounted for through 
statistical means, selection bias cannot be ruled out. Because 
of the small sample size, outcomes should be validated in 
larger populations in order to reduce possible bias.
Conclusions
In conclusion, the low mortality rates and low need for 
new PPI, as well as the favorable hemodynamics make 
both THV appealing with respect to the extension of 
TAVI towards a younger and low-risk population. Beside a 
longer follow-up for both THV, which is needed to retrieve 
information on durability and long-term outcome, further 
research is warranted to assess the finding of higher stroke 
rates with the intra-annular, repositionable Centera SE-
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